NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS-March 2024-www.financetom.com

NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS

Nov 24, 2025 7:47 AM

10:27 AM EST, 11/24/2025 (MT Newswires) -- NeuroSense Therapeutics ( NRSN ) said Monday it has been cleared by US Food and Drug Administration to begin a phase 3 trial for PrimeC to treat amyotrophic lateral sclerosis.

The company aims to enroll its first patient in the coming months. The trial is expected to be conducted in the US and EU and include 300 participants, the company said.

Shares of NeuroSense Therapeutics ( NRSN ) rose by more than 4% in recent trading.

Price: 1.15, Change: +0.05, Percent Change: +4.64

Previous page： What's Going On With Rocket Lab Shares Today? Next page： --Garmin Keeps Quarterly Dividend at $0.75 Per Share, Payable June 28 to Holders of Record on June 17

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

What's Going On With Rocket Lab Shares Today?

Jun 7, 2024

Rocket Lab USA, Inc. ( RKLB ) shares are trading higher on Friday. In a press release, the company announced the launch window for the company’s 50th Electron launch. The mission will deploy five Internet-of-Things satellites for French company Kinéis. “Making it to your first launch is not a given, so reaching 50 Electron launches is an enormous achievement and a rare...

--Garmin Keeps Quarterly Dividend at $0.75 Per Share, Payable June 28 to Holders of Record on June 17

Jun 7, 2024

01:18 PM EDT, 06/07/2024 (MT Newswires) -- Price: 163.74, Change: -0.17, Percent Change: -0.10 ...

Former Allianz employee pleads guilty to fraud over $7 billion funds meltdown

Jun 7, 2024

NEW YORK (Reuters) - A former Allianz fund manager pleaded guilty on Friday over his role in a meltdown of private investment funds sparked by the COVID-19 pandemic, and which according to prosecutors caused $7 billion of investor losses. Gregoire Tournant admitted to two counts of investment adviser fraud, at a hearing before Chief Judge Laura Taylor Swain of the...

Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients

Jun 7, 2024

01:22 PM EDT, 06/07/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday that data from a phase 3 study showed that Trikafta improved lung function compared with placebo in people with cystic fibrosis. Data from the randomized double-blind study showed that lung function improved by 9.2 percentage points as measured by ppFEV1 and pulmonary exacerbations were cut by...